Preclinical Studies
NanoViricides Reports NV-387 Shows Strong Antiviral Activity Against Measles in Preclinical Studies
NanoViricides' clinical lead drug candidate NV-387 demonstrated potent antiviral effects against Measles virus with significant lung protection and extended survival in animal models, potentially offering the first approved treatment for a disease that currently has no specific antiviral therapy.
Lexaria's DehydraTECH Shows Enhanced Brain Delivery of Semaglutide in Preclinical Study
Lexaria Bioscience's drug delivery technology demonstrated improved brain distribution of GLP-1 drug semaglutide in rodents, potentially leading to better safety and efficacy for weight loss treatments.
Clene's CNM-Au8 Shows Promise in Parkinson's Disease Preclinical Study
Clene Inc. presented preclinical data demonstrating its investigational drug CNM-Au8 improves mitochondrial function and reduces inflammation in Parkinson's disease models, potentially offering a new neuroprotective treatment approach.
ReAlta’s Pegtarazimod Demonstrates Potential in Reducing Brain Inflammation in Newborns with HIE
A preclinical study reveals pegtarazimod's ability to significantly reduce brain inflammation in newborns with hypoxic ischemic encephalopathy (HIE), offering hope for a new treatment approach.
Silo Pharma Inc. Anticipates Key Study Results for PTSD Treatment SPC-15
Silo Pharma Inc. is on the verge of receiving crucial preclinical study results for SPC-15, a potential breakthrough in PTSD treatment, marking a significant step towards addressing a long-unmet medical need.
Tonix Pharmaceuticals' TNX-1700 Shows Promise in Enhancing Immunotherapy for Gastric Cancer
Tonix Pharmaceuticals' preclinical data reveals TNX-1700's potential to improve immunotherapy outcomes in gastric cancer by targeting immunosuppressive neutrophils.
Lantern Pharma Shows Promise in Pediatric Brain Cancer Treatment
Lantern Pharma's experimental drug LP-184 demonstrates significant potential in treating atypical teratoid rhabdoid tumors (ATRT), a rare and aggressive pediatric brain cancer, with preclinical studies showing remarkable improvements in survival rates.
Telomir Pharmaceuticals Reveals Promising Vision Restoration in Preclinical AMD Study
Telomir Pharmaceuticals has demonstrated its oral therapeutic candidate Telomir-1 can restore vision and reverse retinal degeneration in a zebrafish model of age-related macular degeneration, highlighting potential breakthrough treatment for vision loss.
Tonix Pharmaceuticals Presents Promising Single-Dose Mpox Vaccine Candidate
Tonix Pharmaceuticals revealed preclinical data for TNX-801, a single-dose mpox vaccine that demonstrates durable protection in animals, including immunocompromised subjects. The vaccine could potentially address global health emergency challenges related to mpox outbreaks.